v3.25.1
Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)
Mar. 31, 2025
Dec. 31, 2024
Schedule of Accrued Expenses and Other Current Liabilities [Abstract]    
Accrued research and development expense $ 1,799,583 $ 1,799,583
Accrued directors and officers (owners) compensation 991,821 1,025,867
Cash portion of the Lind Note repayments 227,284 127,759
Accrued compensation and employee benefits 140,252 126,106
Others 617,879 557,866
Total $ 3,826,819 $ 3,509,422